Pitavastatin slows tumor progression and alters urine‐derived volatile organic compounds through the mevalonate pathway
Authors:
Open Access
- 4 October 2019
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 33 (12) , 13710-13721
Abstract
Bone is a frequent site of metastasis from breast cancer, and a desirable drug could suppress tumor growth as well as metastasis‐linked bone loss. Currently, no drug is able to cure breast cancer‐associated bone metastasis. In this study, we focused on statins that are known to inhibit cholesterol production and act as antitumor agents. After an initial potency screening of 7 U.S. Food and Drug Administration‐approved statins, we examined pitavastatin as a drug candidate for inhibiting tumor and tumor‐induced bone loss. In vitro analysis revealed that pitavastatin acted as an inhibitor of tumor progression by altering stress to the endoplasmic reticulum, down‐regulating peroxisome proliferator‐activated receptor γ, and reducing Snail and matrix metalloproteinase 9. In bone homeostasis, it blocked osteoclast development by suppressing transcription factors c‐Fos and JunB, but stimulated osteoblast mineralization by regulating bone morphogenetic protein 2 and p53. In a mouse model, pitavastatin presented a dual role in tumor inhibition in the mammary fat pad, as well as in bone protection in the osteolytic tibia. In mass spectrometry‐based analysis, volatile organic compounds (VOCs) that were linked to lipid metabolism and cholesterol synthesis were elevated in mice from the tumor‐grown placebo group. Notably, pitavastatin‐treated mice reduced specific VOCs that are linked to lipid metabolites in the mevalonate pathway. Collectively, the results lay a foundation for further investigation of pitavastatin's therapeutic efficacy in tumor‐induced bone loss, as well as VOC‐based diagnosis of tumor progression and treatment efficacy.—Wang, L., Wang Y., Chen, A., Teli, M., Kondo, R. Jalali A. Fan Y. Liu S. Zhao X. Siegel A. Minami K. Agarwal M. Li B.‐Y., Yokota, H. Pitavastatin slows tumor progression and alters urine‐derived volatile organic compounds through the mevalonate pathway. FASEB J. 33, 13710‐13721 (2019). www.fasebj.orgKeywords
Funding Information
- National Institutes of Health (R01AR052144)
- National Institutes of Health (R03CA238555)
This publication has 56 references indexed in Scilit:
- Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblastsCell Death & Disease, 2012
- Bisphosphonates: Mechanism of Action and Role in Clinical PracticeMayo Clinic Proceedings, 2008
- Study of Anoxic and Oxic Cholesterol Metabolism by Sterolibacterium denitrificansJournal of Bacteriology, 2008
- Steroids, triterpenoids and molecular oxygenPhilosophical Transactions of the Royal Society B: Biological Sciences, 2006
- Statins and osteoporosis: new role for old drugsJournal of Pharmacy and Pharmacology, 2006
- The snail superfamily of zinc-finger transcription factorsNature Reviews Molecular Cell Biology, 2002
- Optimising treatment of bone metastases by Aredia™ and Zometa™Breast Cancer, 2000
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000
- Establishment of a clonal osteogenic cell line from newborn mouse calvariaJapanese Journal of Oral Biology, 1981
- Functional macrophage cell lines transformed by abelson leukemia virusCell, 1978